Literature DB >> 17173075

c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.

R C Ishizawar1, T Miyake, S J Parsons.   

Abstract

Overexpression and/or gene amplification of c-Src and members of the epidermal growth factor receptor (EGFR/ErbB) family have been implicated in the pathogenesis of breast cancer. Although members of the EGFR family are known to form heterocomplexes with one another, c-Src has also been shown to physically interact with members of this family in breast cancer cell lines and tumors. This paper investigates the role of c-Src in modulating the physical and functional interaction between ErbB2 and ErbB3, two family members that preferentially associate with one another and together exhibit high oncogenic potential. We show that overexpressed wild-type c-Src enhances heterocomplex formation of ErbB2 and ErbB3 that results in increased basal and/or heregulin-induced activation of receptors, and their downstream intracellular effectors. Expression of a kinase-inactive form of c-Src (K(-) c-Src) or pharmacological inhibition of c-Src by PP2 negatively affects these events. Furthermore, cellular motility and anchorage-independent growth promoted by the ErbB2/ErbB3 heterocomplex are dependent upon c-Src, as demonstrated by the effects of K(-) c-Src overexpression or treatment with PP2. In contrast to previous studies that defined a role for c-Src downstream of ErbB2/ErbB3, the current work suggests an upstream mechanism, whereby c-Src enhances ErbB2/ErbB3 signaling and biological functions by positively modulating the association between ErbB2 and ErbB3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17173075     DOI: 10.1038/sj.onc.1210138

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

Review 1.  SRC: a century of science brought to the clinic.

Authors:  Alexey Aleshin; Richard S Finn
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

2.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

3.  Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma.

Authors:  Xiang H-F Zhang; Xin Jin; Srinivas Malladi; Yilong Zou; Yong H Wen; Edi Brogi; Marcel Smid; John A Foekens; Joan Massagué
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

4.  Development of a highly selective c-Src kinase inhibitor.

Authors:  Kristoffer R Brandvold; Michael E Steffey; Christel C Fox; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2012-06-04       Impact factor: 5.100

5.  ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells.

Authors:  Keneshia K Haenssen; Sarah A Caldwell; Kristina S Shahriari; S Raelle Jackson; Kelly A Whelan; Andres J Klein-Szanto; Mauricio J Reginato
Journal:  J Cell Sci       Date:  2010-03-23       Impact factor: 5.285

6.  Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data.

Authors:  Brendan Boyce; Lianping Xing
Journal:  Clin Investig (Lond)       Date:  2011-12-01

Review 7.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

Review 8.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

9.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

10.  Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.

Authors:  Shannon E Telesco; Ravi Radhakrishnan
Journal:  Biophys J       Date:  2009-03-18       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.